Objective To investigate the anti-tumor effects of photodynamie therapy(PDT)on human pancreatic cancer xenograft in nude mice and the time-effect relationship of PDT.Methods The animal model of human pancreatic cancer was developed by suturing small pieces of SW1990 tumors into the dorsum of nude mice.When the size of the tumors increased to 0.8～1.0 cm.36 mice were randomly divided into three groups:control group(no treatment),photosensitizer group(Photosan 2mg/kg,abdominal cavity injection),photodynamic group(Photosan 2 mg/kg injection+laser irradiation).Each group included 12 mice.The tumor sizes were measured twice per week and the weight8 and volumes of the tumors were measured,and the tumor inhibitory rate was calculated three weeks later.Results The tumor volume of photodynamic group was (0.22±0.12)mm3 at the 6th day,which was significantly smaller than(0.43 s0.18)mm3 of control group and(0.39±0.15)mm3 of photosensitizer group(P＜0.05).15 days later,the tumor volumes of PDT groups increased.21 days later.the weight of the tumors in photodynamie group was(0.69±0.23)g,which was significantly lower than(1.65 ±0.21)g of control group and(1.62±0.12)g of photosensitizer group(P＜0.05).The tumor inhibitory rate in photodynamic group was 58.18%,which was significantly higher than that of photoseasitizer group(1.8%,P＜0.05).Conclusions Photodynamie therapy had significant anti-tumor effect on human pancreatic cancer with quick-acting efficacy,but photodynamie therapy alone exeaed efficacy only in the shoa term.

Objective To investigate the effects of gemcitabine,a cytotoxic drug,combined with photodynamic therapy (PDT) in treatment of human pancreatic cancer xenograft in nude mice.Methods The animal model of human pancreatic cancer was developed by suturing small pieces of SW1990 tumors into the dorsum of nude mice.Sixty animal models were randomly divided into five groups with 12 each:control group ( without any treatment ), photosensitizer group ( 2 mg/kg of Photosan, without illumination ),chemotherapy group (receiving 50 mg/kg of gemcitabine i.p. on day 0,3,6 and 9 after transplantation),photodynamic group (2 mg/kg photosan combined with laser irradiation) and combination group (50 mg/kg of gemcitabine and 2 mg/kg of photosan combined with laser irradiation). The tumor sizes were measured twice every week.All mice were sacrificed after 21 days.The tumor volume was calculated,and inhibitory effect and changes before and after treatment were analyzed.Results The tumor was grown bigger in control,photosensitizer and chemotherapy groups (all P value ＜0.05).On day 6,9,12,15,18and 21, the tumor size was significantly smaller in photodynamic group than those in control and photosensitize groups.While the tumor size on day 18 and 21 was smaller in combined group than those in photodynamic group(all P value ＜0.05). The tumor mass was (0.29 ± 0.20) g in combined group,which was lower than that in photodynamic,control,photosensitize and chemotherapy groups[(0.69±0.23) g,(1.65±0.21) g,(1.62±0.12) g,(1.37±0.19) g,respectively,P＜0.05].The inhibitory effect were 82.420%00 and 58.18% in combined group and photodynamic group,respectively(P＜0.05),while there was 1.80% and 17.00% in photosensitize and chemotherapy groups,respectively.Conclusions Photodynamic therapy has significant and short anti-tumor effect,but it can be significantly enhanced by combined with small dose of gemcitabine.

0.05).After that,both systolic and diastolic function began to decrease.In 4 weeks after the operation,both the the maximum rate of left ventricular isovolumic systolic pressure + dp/dtmax and the maximum rate of left ventricular isovolumic diastolic pressure-dp/dtmax decreased to the lowest levels [(1249.89 ? 95.82) mm Hg/s and(-1316.40 ? 58.31) mm Hg/s,respectively];and then in 6 weeks after the operation,echocardiography showed that the left ventricular short axis fractional shortening FS reached the lowest level [(18.70 ? 3.83)%].Moreover,we found that the FS was highly related with the + dp/dtmax(r=0.864,P

Objective To establish a rapid test method for the determination of five sweeteners and two preservatives in the milk beverage by HPLC.Methods Trough a set of pretreatment such as dilution,protein precipitation,high-speed centrifugation,the samples were tested.With NUCLEODUR C18 RP-column separation,phosphate buffer(pH=5.0) and acetonitrile were used as the mobile phase,gradient elution analysis was conducted,the detective wavelength was 205nm.Results The separation of one sample was achieved within 15 min,five sweeteners and two preservatives could be well separated,the linear range was 5.00-100.0 mg/L,r≥0.9993,RSD was 1.5%-4.2%(n=6),the average recovery rate was 85.2%-108%.Conclusion This method is simple and quick with better reproducibility and selectivity,it is an effective way to determine sweeteners and preservatives in milk beverage.

Objective To observe the differences in the therapeutic efficacies of macrolides,minocycline,and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae(MRMP).Methods A total of 188 children with M.pneumoniae pneumonia confirmed by culture and PCR were analyzed.Of these,150 patients had a strain with an MR gene and 134 had one with an A-to-G mutation at position 2063 of M.pneumoniae 23S rRNA domain V.Azithromycin(n=27),clarithromycin(n=23),tosufloxacin(n=62),or minocycline(n=38)was used for definitive treatment of patients with MR M.pneumoniae.Among the 188 patients,the other 38 patients with macrolide-sensitive Mycoplasma pneumonia (MSMP)were grouped into azithromycin(n =16)and clarithromycin groups(n =22)for observing whether there is differences with respect to efficacy under parallel treatment between patients with MRMP and MSMP. Results Defervescence within 48 h after the initiation of antibiotic therapy was observed in 41%of the patients in the azithromycin group,48% of those in the clarithromycin group,69% of those in the tosufloxacin group,and 87% of those in the minocycline group.The average number of days of fever after the administration of antibiotic treatment was lower in the minocycline and tosufloxacin groups than in the macrolide groups(azithromycin and clarithromycin groups).The decrease in the M.pneumoniae burden,as estimated by the number of DNA copies,after 48 to 96 h of treatment was more rapid in patients receiving minocycline(P=0.016)than in those receiving tosufloxacin(P=0.049),azithromycin(P=0.273),or clarithromycin(P=0.107).Conclusion We found that the clinical and bacteriological efficacies of macrolides against MR M.pneumoniae pneumonia was low.Our results indicated that minocycline rather than tosufloxacin can be considered the first-choice drug for the treatment of M.pneumoniae pneumonia in children aged >8 years.

ObjectiveTo investigate the effect of the immunotherapy of CIK cell, LAK cell and PBLS cell mediated by anti-EGFR/anti-CD3 bispecific antibody (BsAb) respectively on the mice borne human gastric cancer and provide experimental evidence for therapeutic strategy in treating gastric cancer. Methods The mAbs of anti-CD3 and anti-EGFR were cross-linked to prepare the BsAb by chemical synthesis. The experimental therapy on the mice borne SGC7901 human gastric cancer was performed,and then the comparisons of the curative activity among the CIK group, LAK group and PBLS group were conducted in vivo. ResultsThe mean tumor reduction rate of the administration of CIK cells directed by anti-EGFR/anti-CD3 BsAb was(64.9±7.7)％ and higher than those of LAK cells or PBLS targeted by anti-EGFR/anti-CD3 BsAb [(43.5±8.2) ％ and (39.7±6.5) ％] (P ＜ 0.05).The mean tumor weight of the administration of CIK cells directed by anti-EGFR/anti-CD3 BsAb was (473.9±37.7) mg at the end of therapy and was lower than those of LAK cells or PBLS targeted by anti-EGFR/anti-CD3 BsAb [(764.6±88.3) mg and (829.1±104.4) mg](P ＜ 0.05). ConclusionThe CIK cell mediated by anti-EGFR/anti-CD3 BsAb could have better curative effect than other effector cells on gastric cancer in vivo.

ObjectiveTo establish a analytical system for the survival motor neuron (SMN) subtle mutation,and evaluate its application in two families with spinal muscular atrophy (SMA).MethodsSMN genes in seven family members from two SMA families were analyzed at both transcript level and genomic level,by the use of the conventional PCR-RFLP,allele-specific PCR,multiplex ligation-dependent probe amplification (MLPA) and T subcloning and sequencing of SMNI gene.ResultsIn family A,the patient had a single SMN1 copy who was carrying nonsense mutation L228X,which was also found in his father.In family B,as the patient's sample was unavailable,the father was indeed a carrier with one normal SMN1 allele and the other SMN1 allele carrying a frameshift mutation 22_23insA.The remaining family members were SMA carriers with one SMN1 copy.ConclusionThis analytical system for SMN subtle mutation offers viable molecular basis for genetic counseling and prenatal diagnosis in SMA families.

AIM: The plasma concentration-time curve,pharmacokinetic parameters and bioavilability of puerarin,the main active constituent of Yufeng Ningxin Tablets(total flavone of Radix Puerariae Lobatae) in dog by(oral) administration was determined,and the pharmacokinetics was compared with puerarin injection by intravenous injection individually. METHODS: A single dose(the puerarin amount to 10.49 mg/kg) of Yufeng Ningxin Tablets by oral administration and puerarin injection by intravenous injection(9 mg/kg) were given to dogs in a auto-control way. The concentration of puerarin in plasma was determined by HPLC.The PK solutions 2.0 program,a non-compartmental model software,was applied to calculate the pharmacokinetic parameters. RESULTS: 1.The pharmacokinetic parameters of puerarin in dog showed that the t_(1/2E) f puerarin injection(9 mg/kg) by i.v was(72.11)?3.69 min,CL was 4.19?0.25 mL/min,AUC_((0-∞)) was 2172.42?123.02 ?g/min/mL,and the t_(1/2E) of puerarin in Yufeng Ningxin Tablets(10.49 mg/kg) by oral administration was 271.80?7.94 min, CL was 48.52?(2.20) mL/min,C_(max) was 0.43?0.06 ?g/mL, T_(max) was 150 min, AUC_((0-∞)) was 185.77?8.20 ?g/min/mL,and bioavailability was 7.03% compared to puerarin injection by intravenous injection. CONCLUSION: The absorption of puerarin in Yufeng Ningxin Tablets by oral administration comparing with puerarin injection by intravenous injection in dog is very poor,and the bioavailabilites is also low.

Objective To establish an otitis media with effusion model in rat,and provide a pure physical approach of animal model for researching the otitis media with effusion.Methods Twenty-four clean grade male SD rats were selected.Only the right ears were used for the model group,the contralateral ears were used as the control group.The animal model of otitis media with effusion was established by blocking eustachian tube with cork stopper through the right side mandible,the hearing was evaluated by ABR and tympanogram configurations,the pathologic changes of middle ear and eustachian tube mucous membrane were examined by light microscopy.Results Twenty out of 24 ears of rats' of hearing threshold increased from 34.25?5.45 dB to 57.63?5.46 dB (P

Objective To evaluate the pharmacokinetic parameters and bioavailability of puerarin in Yufeng Ningxin tablets in mice by determining dose-time curve and by comparing with the pharmacokinetics of puerarin injection.Methods NIH mice were randomized into different groups. 6 %HClO4 was used to precipitate plasma protein and the plasma concentration of puerarin in mice was determined by HPLC.The PK solutions 2.0 program,a non-compartmental model software,was applied to calculate the pharmacokinetic parameters and bioavailability.Results The main pharmacokinetic parameters of puerarin injection by i.v.in mice were:t1/2=98.359 min,CL=35.548 mL?min-1,AUC(0-∞)=281.3 ?g?min?mL-1;the main pharmacokinetic parameters of puerarin in Yufeng Ningxin tablets by o.p.were:t1/2 =35.562 min,CL=898.685 mL?min-1,Cmax=9.3 ?g?mL-1,Tmax=30 min,AUC(0-∞)=222.5 ?g?min?mL-1 ,F(bioavailability value)=3.95 %comparing to puerarin injection.Conclusion As compared with puerarin injection,the absorptive content of puerarin in Yufeng Ningxin tablets is very poor and the bioavailability is also low,indicating that enhancement of bioavailability of Yufeng Ningxin tablets will be beneficial to the clinical application.